Study of physiological parameters in COVID-19 Disease
Not Applicable
- Conditions
- Health Condition 1: A00-B99- Certain infectious and parasitic diseasesHealth Condition 2: B972- Coronavirus as the cause of diseases classified elsewhere
- Registration Number
- CTRI/2021/04/032943
- Lead Sponsor
- Dr Pallavi Yuvaraj Badhe
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Male and female COVID swab positive patients having age >= 18 year
Exclusion Criteria
Exclusion Criteria:
Patients on drug affecting cardiac function( altering ECG waves) :Antiarrhythmic drugs: Disopyramide, Propafenone and flecainide, Amiodarone, Beta blockers, Digitalis, HCQ, Quinidine, Anthracycline Antibiotics- doxorubicin and daunorubicin
Diagnosed chronic heart diseases: like Chronic ischemic changes, valvular disorder, cardiac hypertrophies, COPD, Congenital heart disease
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Weather ECG within 1 day of hospital admission can be used as prognostic marker or not will be clear. There might be significant changes in physiological variables in COVID- 19 patients and when these changes will be analyzed statistically, we might get significant results, which may be helpful to clinicians to treat reversible cardiovascular complications.Timepoint: Data Collection 1 month <br/ ><br>Data Entry & Compilation 15 days <br/ ><br>Data Analysis 15 days <br/ ><br>Manuscript Preparation 1 month
- Secondary Outcome Measures
Name Time Method Clinical profile of COVID-19 will be clearTimepoint: Within 6 months